Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
6.39
Nov 20 • 3:59 PM ET Dollar change+0.02 Percentage change(0.31%)
Aftermarket Close
6.39
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
242.22M
Enterprise Value
432.49M
Income
-
Sales
-
Book/sh
-1.94
Cash/sh
0.61
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Feb 15, 1996
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
10.51
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.59
Current Ratio
3.84
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
31.55% 0.55%
Sales past 3/5Y
5.02% -26.24%
EPS Y/Y TTM
-430.88%
Sales Y/Y TTM
-
EPS Q/Q
-271.49%
Sales Q/Q
-18.60%
Insider Own
9.60%
Insider Trans
0.00%
Inst Own
67.27%
Inst Trans
0.91%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-0.35%
SMA50
6.28%
SMA200
19.13%
Trades
Shs Outstand
37.91M
Shs Float
34.27M
52W High
8.98 -28.84%
52W Low
3.62 76.28%
Volatility
0.46% 0.73%
ATR (14)
0.06
RSI (14)
59.27
Beta
0.95
Rel Volume
0.54
Avg Volume
408.33K
Volume
218,574
Perf Week
-0.47%
Perf Month
0.31%
Perf Quarter
40.44%
Perf Half Y
29.61%
Perf YTD
-21.88%
Perf Year
-13.30%
Perf 3Y
-14.00%
Perf 5Y
-32.67%
Perf 10Y
-55.63%
Prev Close
6.37
Price
6.39
Change %
0.31%
Consensus
Hold
Avg. Price Target
$6.28
Implied Upside
-1.7%
Analysts5incl. previous ratings
Rating Distribution3 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 17, 2026Upgrade
BBarrington Research
Mkt Perform → Outperform$5.50-13.9%
Sep 04, 2025Initiated
KEY logoKKeyBanc Capital Markets
Sector Weight
May 21, 2025Initiated
WWilliam Blair
Outperform
Sep 05, 2024Initiated
CCraig Hallum
Buy$8+25.2%
Aug 28, 2024Downgrade
BBarrington Research
Outperform → Mkt Perform
Mar 20, 2023Downgrade
SStephens
Overweight → Equal-Weight$11 → $2-68.7%
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.
PresidentMr. Paul Josephs
Executive VP & CFOMr. Ryan D. Lake CPA
Chief Legal & Administration Officer and Corporate SecretaryMr. Thomas D. Salus
Vice President of OperationsMr. Thomas Guldager
Executive Vice President of Quality & Development ServicesMs. Jackie Q. Klecker